Chargement en cours...

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir. Risk fo...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Pharmacol Ther
Auteurs principaux: Gammal, RS, Court, MH, Haidar, CE, Iwuchukwu, OF, Gaur, AH, Alvarellos, M, Guillemette, C, Lennox, JL, Whirl‐Carrillo, M, Brummel, SS, Ratain, MJ, Klein, TE, Schackman, BR, Caudle, KE, Haas, DW
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2015
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4785051/
https://ncbi.nlm.nih.gov/pubmed/26417955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.269
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!